Savvy Trades and Investments

[wadegarret]

Hweb- GERN

Well they make no money, so no comment on that of course. However I do see that they are making progress in their phase 3 study for the use of Imetelstat for Myelofibrosis(which there is no treatment for when relapsed). Also it seems there are no changes in positive patient outcomes of transfusion independence for the use of Imetelstat for low risk MDS(which is what they are waiting FDA approval on). So I have no idea about the volatility. March 14 will be important as the Oncology Advisory Committee will be meeting to discuss Imetelstat, and their view to the FDA. JAMA has a study out that states, when the Oncology Advisory Committee is positive on a drug, it gets approved 97% of the time. I continue to believe GERN will be a big winner from the $2 price.